Trial Profile
A Phase 2, 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Two Injections of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Lorecivivint (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Biosplice Therapeutics
- 03 Jun 2023 Results assessing safety, efficacy, and bone health utilizing quantitative computed tomography (Qct) in Knee Osteoarthritis (n=101) presented at the 24th Annual Congress of the European League Against Rheumatism.
- 14 Nov 2022 Results presented at the ACR Convergence 2022
- 11 Nov 2022 According to a Biosplice Therapeutics media release, data from the trial will be presented at the 2022 ACR Annual Meeting.